Zenas BioPharma, Inc. Increase (Decrease) in Accounts Payable
Zenas BioPharma, Inc. (ZBIO) reported Increase (Decrease) in Accounts Payable of $461.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-13
- Zenas BioPharma, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$1.33M.
- Zenas BioPharma, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $1.79M, a 37.72% decline year-over-year.
- Zenas BioPharma, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $1.12M, a 79.41% decline year-over-year.
- Zenas BioPharma, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$1.95M, a 157.61% decline year-over-year.
- Zenas BioPharma, Inc. increase (decrease) in accounts payable for fiscal 2025 was -$10.04M, a 185.55% decline from fiscal 2024.
- Zenas BioPharma, Inc. increase (decrease) in accounts payable for fiscal 2024 was $11.74M.
- Zenas BioPharma, Inc. increase (decrease) in accounts payable for fiscal 2023 was -$418.00K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $461.00K 10-Q · filed 2026-08-13 | $1.58M derived: sum of 3 quarters · filed 2026-08-13 | -$377.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.79M 10-Q · filed 2026-05-13 | $2.91M derived: sum of 2 quarters · filed 2026-05-13 | $957.00K derived: sum of 3 quarters · filed 2026-05-13 | -$11.13M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$838.00K derived: sum of 2 quarters · filed 2026-03-16 | -$12.93M derived: sum of 3 quarters · filed 2026-08-13 | -$10.04M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$1.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$14.04M derived: sum of 2 quarters · filed 2026-08-13 | -$11.16M 10-Q · filed 2025-11-12 | -$5.74M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$12.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$9.21M 10-Q · filed 2026-08-13 | -$3.78M derived: sum of 3 quarters · filed 2026-08-13 | -$392.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $2.88M 10-Q · filed 2026-05-13 | $8.30M derived: sum of 2 quarters · filed 2026-05-13 | $11.70M derived: sum of 3 quarters · filed 2026-05-13 | $11.21M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $5.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $8.81M derived: sum of 2 quarters · filed 2026-03-16 | $8.33M derived: sum of 3 quarters · filed 2026-03-16 | $11.74M 10-K · filed 2026-03-16 |
| 2024-09-30 | $3.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.91M derived: sum of 2 quarters · filed 2025-11-12 | $6.32M 10-Q · filed 2025-11-12 | $9.44M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$480.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $2.93M 10-Q · filed 2025-08-12 | $6.05M derived: sum of 3 quarters · filed 2025-08-12 | |
| 2024-03-31 | $3.41M 10-Q · filed 2025-05-15 | $6.53M derived: sum of 2 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $3.12M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$418.00K 10-K · filed 2025-03-11 | ||
| 2023-09-30 | -$3.54M 10-Q · filed 2024-11-12 |